CGTX - NASDAQ

Cognition Therapeutics, Inc.

CGTX·NASDAQ

$1.42

+14%

HealthcareBiotechnology

Cognition Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of small molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its lead product candidate is CT1812, a sigma-2 receptor antagonist, which is in Phase II clinical trial for the treatment of mild-to-moderate Alzheimer's disease, as well as has completed Phase I clinical trial to treat early-stage Alzheimer's disease; in Phase II clinical trial for the treatment of dementia with Lewy bodies (DLB); and in preclinical trial to treat dry age-related macular degeneration (AMD). The company is also developing CT2168 for the treatment of synucleinopathies, which include DLB and Parkinson's disease; and CT2074 to treat dry AMD. Cognition Therapeutics, Inc. was incorporated in 2007 and is headquartered in Purchase, New York.

Statements Value Model

At a Glance

Live Snapshot

Market Cap$104.49M

EPS-0.3200

P/E Ratio-4.44

Earnings Date08/06/2026

48.39M

Assets

60%

3Y-4.0%

5Y+580.0%

10Y+549.0%

14.12M

Total Liabilities

23%

3Y+39.0%

5Y-81.0%

10Y-79.0%

34.27M

Total Equity

83%

3Y-15.0%

5Y-150.0%

10Y-159.0%

Cognition Therapeutics, Inc. Funding & Solvency Profile

CGTX · NASDAQ

Current Assets

Cash & Cash Equivalents36.81M

Net Receivables9.92M

Inventory0.00

Other Current Assets1.26M

Total Current Assets48 M

Non-Current Assets

Property, Plant & Equipment399.00K

Goodwill & Intangible Assets0.00

Long-Term Investments0.00

Other Non-Current Assets0.00

Total Non-Current Assets399 K

Total Assets

48.39M

Financial Health Analysis

Current Ratio

3.45x

Excellent liquidity position. The company can easily cover its short-term obligations with substantial cushion.

Debt-to-Equity Ratio

0.41x

Conservative capital structure. The company relies primarily on equity financing, indicating low financial risk.

Working Capital

34 M

Strong working capital position provides significant operational flexibility and financial cushion.

Asset Composition

99% Current

Asset-light business model with high liquidity. Majority of assets are easily convertible to cash.

Financial Health Insight

Strong financial foundation: Excellent liquidity combined with conservative leverage suggests the company is well-positioned to weather economic uncertainties and fund growth opportunities.

Cognition Therapeutics, Inc. Balance Sheet

CGTX • NASDAQ

Cognition Therapeutics, Inc. Balance Sheet	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020	Dec 2019
ASSETS
CURRENT ASSETS
Cash and Cash Equivalents	36.8M	25M	29.9M	41.6M	54.7M	5.2M	2.9M
Cash & Short-Term Investments	36.8M	25M	29.9M	41.6M	54.7M	5.2M	2.9M
Net Receivables	9.9M	2.7M	1.3M	3.7M	2.3M	1.2M	4.1M
Other Receivables	9.9M	2.7M	1.3M	3.7M	2.3M	1.2M	4.1M
Inventory	0.0	0.0	0.0	0.0	0.0	0.0	117K
Prepaids	0.0	1.9M	0.0	2.4M	2M	544K	117K
Other Current Assets	1.3M	0.0	3M	0.0	11K	23K	-88K
Total Current Assets	48M	29.6M	34.2M	47.6M	59M	6.9M	7.2M
NON-CURRENT ASSETS
Property, Plant, and Equipment (Net)	399K	679K	941K	1M	145K	211K	299K
Other Non-Current Assets	0.0	0.0	0.0	1.7M	0.0	0.0	0.0
Total Non-Current Assets	399K	679K	941K	2.8M	145K	211K	299K
Total Assets	48.4M	30.2M	35.2M	50.4M	59.1M	7.1M	7.5M
LIABILITIES
CURRENT LIABILITIES
Total Payables	1.1M	2M	3.7M	3.2M	4.2M	2M	2.4M
Accounts Payable	1.1M	2M	3.7M	3.2M	4.2M	2M	2.4M
Accrued Expenses	0.0	6.1M	2.9M	1.2M	466K	262K	532K
Short Term Debt	443K	279K	544K	634K	0.0	0.0	0.0
Capital Lease Obligations (Current)	0.0	193K	174K	149K	0.0	0.0	4K
Deferred Revenue	367K	1.1M	1.7M	1.7M	753K	0.0	1.3M
Other Current Liabilities	12M	1.5M	1.2M	870K	2.5M	985K	-531K
Total Current Liabilities	13.9M	11.1M	10.2M	7.8M	7.9M	3.3M	3.7M
NON-CURRENT LIABILITIES
Long Term Debt	0.0	0.0	0.0	0.0	0.0	12.9M	6.9M
Deferred Revenue (Non-Current)	0.0	0.0	0.0	1.7M	0.0	0.0	0.0
Deferred Tax Liabilities (Non-Current)	0.0	0.0	0.0	-695K	0.0	0.0	0.0
Other Non-Current Liabilities	0.0	0.0	0.0	695K	0.0	59.2M	55.3M
Total Non-Current Liabilities	195K	342K	520K	2.4M	0.0	72.1M	62.2M
Capital Lease Obligations	195K	535K	694K	844K	0.0	0.0	4K
Total Liabilities	14.1M	11.5M	10.7M	10.2M	7.9M	75.3M	65.9M
SHAREHOLDERS' EQUITY
Preferred Stock	0.0	0.0	0.0	0.0	0.0	0.0	52.9K
Common Stock	90K	60K	32K	29K	22K	1K	1K
Additional Paid-In Capital	232.8M	193.9M	165.8M	155.8M	145.5M	222K	1K
Retained Earnings	-198.6M	-175.2M	-141.2M	-115.4M	-94M	-68.2M	-58.2M
Accumulated Other Comprehensive Income/Loss	0.0	0.0	-195K	-199K	-198K	-187K	-185K
Total Stockholders' Equity	34.3M	18.8M	24.5M	40.2M	51.3M	-68.2M	-58.4M
Total Equity	34.3M	18.8M	24.5M	40.2M	51.3M	-68.2M	-58.4M
SUMMARY
Total Liabilities & Equity	48.4M	30.2M	35.2M	50.4M	59.1M	7.1M	7.5M
Total Debt	638K	814K	1.2M	1.5M	0.0	12.9M	6.9M
Net Debt	-36.2M	-24.2M	-28.7M	-40.1M	-54.7M	7.7M	4M
Shares Outstanding	73,582,191	73,582,191	73,582,191	73,582,191	73,582,191	73,582,191	73,582,191

SEC Filings

CGTX - Filing history and reports

Filing Type	Filing Date	Period Ending	Fiscal Year	Actions
8-K 8-K 2026 N/A	May 21, 2026	May 21, 2026	2026	View Filing
10-Q 10-Q 2026 Q1 Q1	May 08, 2026	March 31, 2026	2026	View Filing
8-K 8-K 2026 N/A	May 07, 2026	May 07, 2026	2026	View Filing
DEF 14A DEF 14A 2026 N/A	April 27, 2026	June 17, 2026	2026	View Filing
10-K 10-K 2025 FY FY	March 26, 2026	December 31, 2025	2025	View Filing
8-K 8-K 2026 N/A	March 26, 2026	March 26, 2026	2026	View Filing
8-K 8-K 2026 N/A	March 02, 2026	March 02, 2026	2026	View Filing
8-K 8-K 2026 N/A	January 27, 2026	January 27, 2026	2026	View Filing
8-K 8-K 2025 N/A	December 18, 2025	December 16, 2025	2025	View Filing
S-3 S-3 N/A	December 18, 2025	December 18, 2025		View Filing

Showing 1 to 10 of 100 filings

Related Guides

Blog Categories

Continue your CGTX research with focused valuation guides.

Fundamentals

Decode statement quality and operating durability.

Accounting

Interpret line items with cleaner analytical framing.

Forecasting

Translate historical performance into forward scenarios.

Reference

Use practical frameworks for statement-led valuation.

Research Paths

Pick your next lens

Snapshot

Start with context, operating signals, and key market metrics.

Value Model

Stress test fair value across bear, base, and bull assumptions.

Statements

Validate revenue quality, margins, and balance sheet durability.

Earnings Call

Read management commentary and compare it with reported outcomes.

Dividends

Check payout sustainability and long-term distribution behavior.

Analyst Expectations

Review consensus spread and where estimate risk is concentrated.